CA
NZ
UK
AU
IND
US
Cytokinetics, Incorporated (NASDAQ: CYTK) operates in the pharmaceuticals sector with a market valuation of $10.1 billion. The company recently reported revenues of $88.04 million and maintains approximately $255.27 million in cash and equivalents against aDebtload of $275.56 million. With a negative netMarginof -1321.1%, it …
Grace Therapeutics, Inc. (NASDAQ: GRCE) operates as a late-stage biopharmaceutical company with a market capitalization of $34 million. It is specifically focused on developing GTx-104, an injectable formulation aimed at progressing through the regulatory gauntlet for treating aneurysmal subarachnoid hemorrhage (aSAH). Recently, the company …
Lucid Diagnostics Inc. (NASDAQ: LUCD) operates within the healthcare sector as a commercial-stage medical diagnostics company focused on cancer prevention, boasting a marketCapitalizationof approximately $195 million. Despite facing net losses, Lucid continues to build momentum, reporting $1.5 million in revenue for the second quarter …
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company dedicated to developing therapies for cancer, demonstrated by its marketCapitalizationof approximately $1 billion. The company reported zeroRevenuein the past year, reflecting its focus on research and development, while holding significant cash and equivalents of …
PTC Therapeutics, Inc. (NASDAQ: PTCT) commands a market capitalization of roughly $6.2 billion and reports a price‑to‑sales multiple of 6.7. The firm generated $1.01 billion in trailing‑twelve‑month revenue, a 42.8% decline year‑over‑year, and posted a netMarginof -3.8%. With 991 employees, $1.05 billion of cash …
The company operates with reported debt of $8.91 million against $9.61 million in cash and equivalents. These figures indicate a relatively stableLiquidityposition. However, Rockwell faces significant challenges as it continues to report declining revenues alongside negative net margins, drawing attention from investors who closely …
LENSAR, Inc. achieved notable success in its second quarter of 2026, reporting an 18% increase in revenue compared to previous periods. This growth was largely driven by a remarkable 23% rise in procedure revenue, indicating heightened utilization of its ALLY laser cataract surgery system. …
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology firm specializing in solutions for neurological disorders, achieved a significant revenue milestone of $2 million in Q3 2026, marking a 16% year-over-year increase from $1.7 million in the prior year. This growth underscores the company's …
Pelthos Therapeutics Inc. (NYSE American: PTHS) is a biopharmaceutical firm focused on innovative therapeutic products targeting unmet patient needs, especially in dermatological conditions. As it reports its financial results for the second quarter of 2026, Pelthos achieved an astounding 3100% revenue surge, elevating quarterly …
Recent discussions around prescription drug pricing highlight a growing concern: many consumers are facing costs that exceed their monthly mortgage payments. This troubling trend has brought to light the underlying issues in the current pharmaceutical pricing model, where companies often base drug costs on …
Please wait processing your request...